MFN2 Gene CMT2A2 NGS Genetic DNA Test
Comprehensive Genetic Testing for Neurological Disorders
The MFN2 Gene CMT2A2 NGS Genetic DNA Test represents a breakthrough in neurological genetic diagnostics, offering precise detection of mutations responsible for Charcot-Marie-Tooth disease type 2A2. This advanced testing methodology provides crucial insights for patients and healthcare providers seeking definitive answers about inherited neurological conditions.
What Does This Test Measure?
This specialized genetic test utilizes Next Generation Sequencing (NGS) technology to analyze the MFN2 gene for specific mutations associated with CMT2A2. The test examines:
- Complete sequencing of the MFN2 gene coding regions
- Detection of point mutations, insertions, and deletions
- Identification of pathogenic variants linked to neurological dysfunction
- Assessment of mitochondrial fusion protein abnormalities
Who Should Consider This Test?
Individuals experiencing the following symptoms or family history patterns should consider the MFN2 Gene CMT2A2 NGS Genetic DNA Test:
- Progressive muscle weakness in feet and hands
- High arches or foot deformities (pes cavus)
- Reduced sensation in extremities
- Family history of Charcot-Marie-Tooth disease
- Difficulty walking or frequent tripping
- Muscle atrophy in lower legs
- Delayed motor development in childhood
- Sensory loss affecting temperature and vibration perception
Key Benefits of MFN2 Genetic Testing
Undergoing this comprehensive genetic analysis provides numerous advantages for patients and their families:
- Definitive Diagnosis: Confirms or rules out CMT2A2 with high accuracy
- Early Intervention: Enables proactive management strategies
- Family Planning: Provides crucial information for genetic counseling
- Personalized Treatment: Guides targeted therapeutic approaches
- Prognostic Information: Helps predict disease progression patterns
- Research Contribution: Advances understanding of neurological genetics
Understanding Your Test Results
Your MFN2 genetic test results will be carefully interpreted by our expert genetic counselors and neurologists:
- Positive Result: Indicates the presence of a pathogenic MFN2 mutation associated with CMT2A2
- Negative Result: Suggests no detectable MFN2 mutations, though other genetic causes may need investigation
- Variant of Uncertain Significance: Identifies genetic changes requiring further clinical correlation
- Carrier Status: Determines inheritance patterns for family members
Test Pricing Information
| Test Component | Price (USD) |
|---|---|
| Discount Price | $500 |
| Regular Price | $700 |
Test Specifications
- Turnaround Time: 3 to 4 Weeks
- Sample Type: Blood, Extracted DNA, or One Drop Blood on FTA Card
- Methodology: Next Generation Sequencing (NGS) Technology
- Specialty: Neurology and Genetics
Pre-Test Requirements
Before undergoing the MFN2 Gene CMT2A2 NGS Genetic DNA Test, patients should complete:
- Comprehensive clinical history documentation
- Genetic counseling session with certified genetic counselor
- Development of detailed family pedigree chart
- Discussion of testing implications and potential outcomes
Nationwide Testing Availability
We proudly offer the MFN2 Gene CMT2A2 NGS Genetic DNA Test across our extensive network of testing facilities throughout the United States. Our state-of-the-art laboratories serve patients in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose.
Take Control of Your Neurological Health
Don’t let uncertainty about neurological symptoms affect your quality of life. The MFN2 Gene CMT2A2 NGS Genetic DNA Test provides the clarity needed for informed healthcare decisions and personalized treatment planning.
Book your MFN2 genetic test today by calling our dedicated genetics team at +1(267) 388-9828 or schedule your appointment online. Take the first step toward understanding your genetic health and managing neurological conditions effectively.
